While the impact of the COVID-19 pandemic continues to unfold, distributors are taking proactive steps and working closely with the broader healthcare community to respond to the crisis and prevent disruptions to the pharmaceutical supply chain. As the logistics experts of healthcare, our commitment is to ensure that providers, pharmacies and the patients they serve have access to the vital medicines and supplies they need during these challenging times.
As the impact of COVID-19 “coronavirus” pandemic continues to unfold, we are all deeply concerned about our personal health and well-being — and that of our loved ones. As Americans worry about when their workplaces or schools will reopen, or if they have an adequate supply of necessary household staples, many also have heightened concerns about whether they will be able to access the vital medications and healthcare products they rely on each day.
The core mission of pharmaceutical distribution — secure, efficient and reliable healthcare delivery — provides more than 180 million patients across the United States with efficient and low-cost access to more than 4 billion prescription medicines each year. But distributors’ work does not end there.
HDA has published “A Year in Review,” which chronicles the Alliance’s 2019 activities. Highlighted accomplishments include:
With 2020 underway, HDA’s John M. Gray provided perspective on the vital role of pharmaceutical distributors and the Alliance’s policy priorities as part of Chain Drug Review’s annual “Pharmacy Outlook” feature.
Distributors sit at the heart of the pharmaceutical supply chain, connecting 180,000 healthcare providers and pharmacies with 1,300 drug manufacturers. Through their partnerships across the industry, pharmaceutical distributors provide the more than 180 million patients who regularly take prescription medicines with safe, quick and low-cost access to more than 4 billion prescription medicines each year.
In October 2018, the SUPPORT for Patients and Communities Act was signed into law. This bipartisan legislation offered a comprehensive response to the prescription opioid abuse epidemic — its enactment marked a significant step towards advancing meaningful solutions to address this public health crisis.
It has been clear for some time that the pharmaceutical supply chain has been concerned with meeting the November 27, 2019, saleable returns milestone. As the HDA’s Research Foundation’s annual Serialization Readiness Survey (conducted in May) notes, 79 percent of manufacturers have concerns with the viability of the Verification Router Service (VRS), while 82 percent of distributors are unsure about meeting the requirement.
The U.S. pharmaceutical supply chain is responsible for providing patients safe, secure and timely access to more than 4 billion prescription medicines every year. Sustaining this complex supply chain requires the collaboration between a diverse group of partners, including manufacturers, distributors, pharmacies as well as other healthcare facilities and providers.